Tigris Pharmaceuticals

Tigris Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutic technologies for oncology and other unmet medical needs. Its products include amino flavones for the treatment of renal cell carcinoma, breast cancer, and lung cancer; GGTI-2418, a peptidomimetic inhibitor of synthetic geranylgeranyl transferase for the treatment of lung cancer, breast cancer, pancreatic cancer, and ovarian cancer; and GFB-204, a calixarene derivative that acts as a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation for the treatment of prostate, pancreatic, lung, breast, and renal cell cancers.